Frequency of Helicobacter pylori nitroreductase RdxA mutations for metronidazole activation in a population in the Cauca Department, Colombia

Biomédica : revista del Instituto Nacional de Salud
Claudia Patricia AcostaAlba A Trespalacios

Abstract

Resistance to metronidazole is a key factor associated with Helicobacter pylori treatment failure. Even though resistance is mostly associated with RdxA nitroreductase mutations, studies of this H. pylori protein in Popayán (Colombia) are still incipient. To evaluate the frequency of mutations in the RdxA nitroreductase in a population of patients with H. pylori-positive gastrointestinal disease. We amplified the DNA of 170 gastric biopsies by PCR to detect mutations in the RdxA nitroreductase. An analysis of DNA sequences translated into amino acid sequences was done and then compared to the reference strain 26695. The frequency of RdxA nitroreductase mutations in this study population was 78%. Its most frequent distribution was found in positions D59N (153 samples), R131K (101 samples), R90K (97 samples), A118T (42 samples), I160F (32 samples) and H97T (26 samples), and meaningful stop codons Q50*, D59*; E75*, C159* and I160* in five, one, three, ten and six samples, respectively. The most common virulence genotype was vacAs1/m1 cagA negative (48.6 %). The high frequency of RdxA nitroreductase mutations in H. pylori isolates in Popayán (Colombia) indicates that empirical therapy with metronidazole may not be a valid option fo...Continue Reading

References

Jul 15, 1999·The Journal of Antimicrobial Chemotherapy·P J JenksA Labigne
Feb 13, 2001·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·N Maggi-SolcàJ C Piffaretti
Sep 27, 2001·Canadian Journal of Gastroenterology = Journal Canadien De Gastroenterologie·M Stolte, A Meining
Aug 6, 2002·Trends in Microbiology·George L Mendz, Francis Mégraud
Nov 8, 2002·Journal of Chemotherapy·E Garza-GonzálezF J Bosques-Padilla
Mar 22, 2003·Research in Microbiology·Armelle MaraisFrancis Mégraud
Jun 6, 2003·Alimentary Pharmacology & Therapeutics·F Mégraud, H Lamouliatte
Apr 28, 2005·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Luis Perez AldanaDong H Kwon
Oct 28, 2006·The Lancet Infectious Diseases·Monique M GerritsJohannes G Kusters
Feb 19, 2009·Antimicrobial Agents and Chemotherapy·N O KaakoushG L Mendz
Feb 5, 2011·Nature Reviews. Gastroenterology & Hepatology·Emiko RimbaraDavid Y Graham
Feb 7, 2012·Lancet·Luigi GattaDino Vaira
Apr 12, 2012·Gut·Peter MalfertheinerUNKNOWN European Helicobacter Study Group
Jul 26, 2012·Gastroenterology Research and Practice·Wenming WuGang Sun
Aug 8, 2012·Nature Reviews. Genetics·Xavier DidelotDerrick W Crook
Mar 5, 2014·The American Journal of Gastroenterology·M Constanza CamargoCharles S Rabkin
Apr 25, 2014·Advanced Biomedical Research·Nasrin MirzaeiHajieh Ghasemian Safaei
Jun 11, 2014·World Journal of Gastroenterology : WJG·Jun Heo, Seong Woo Jeon
Jan 1, 2014·Brazilian Journal of Microbiology : [publication of the Brazilian Society for Microbiology]·Silvio Kazuo OgataElisabete Kawakami

❮ Previous
Next ❯

Citations

Jan 10, 2020·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Aining ChuYuehua Gong

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

© 2022 Meta ULC. All rights reserved